中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy

文献类型：期刊论文

作者Xu, Liwei3; Qi, Yajun2; Jiang, Youhua3; Ji, Yongling1; Zhao, Qiang3; Wu, Jie3; Lu, Weishan3; Wang, Yinjie3; Chen, Qixun3; Wang, Changchun3
刊名ANNALS OF TRANSLATIONAL MEDICINE
出版日期2022-03-18
关键词Gut microbiome esophageal squamous cell carcinoma (ESCC) neoadjuvant therapy immunotherapy
ISSN号2305-5839
DOI10.21037/atm-22-1165
通讯作者Chen, Qixun(chenqixun64@163.com) ; Wang, Changchun(sbl0363@dingtalk.com)
英文摘要Background: The gut microbiome is associated with the response to immunotherapy in a variety of advanced cancers. However, the influence of the gut microbiome on locally advanced esophageal squamous cell carcinoma (ESCC) during programmed cell death protein 1 (PD-1) antibody immunotherapy plus chemotherapy is not clearly demonstrated. To explore the crosstalk between the gut microbiome and clinical response in locally advanced thoracic ESCC during neoadjuvant camrelizumab and chemotherapy Methods: Patients who were diagnosed with locally advanced thoracic ESCC and had not received treatment were enrolled. The treatment regimen was two cycles of camrelizumab combined with carboplatin and albumin paclitaxel before surgery. The research endpoints were pathological complete response (pCR) and major pathological response (MPR). Fecal samples were collected at three time points: before neoadjuvant therapy, after two cycles of neoadjuvant therapy, and after surgery. We performed 16S ribosomal ribonucleic acid (rRNA) V3-V4 sequencing of the gene amplicons of fecal samples, as well as bacterial diversity and differential abundance analyses. Results: A total of 46 patients were recruited, and 44, 42, and 35 fecal samples were collected at the three time points, respectively. Statistically significant differences were observed in the amplicon sequence variant (ASV)-level alpha diversity indices, including Chaol, Shannon, and Good's coverage, between the three time points. The non-pCR-enriched gut microbiota included Proteobacteria, Dialister, Aeromonadalcs, Pseudomonadales, Thermi, Deinococci, Moraxellaceae, Rhodocyclales, Rhodocyclaceae, and Acinetobactcr. he non-MPR-enriched gut microbiota included Pseudomonadales and the mitochondria family. The MPR-enriched gut microbiota included the Barnesiellaceae, Pyramidobacter, Dethiosulfovibrionaceae, Odoribacteraceae, Butyricimonas, Prevotella, Barnesiella, and Odoribacter. Patients with >= 3 grade adverse events (AEs) exhibited enrichment in the Succiniclasticum, Nakamurella, Rhizobium, Granulicella, Phyllobacteriaceae, Pelagibacteraceae, Actinosynnemataceae, Aquirestis, Flavisolibacter, Chelativorans, Coxiellaceae Acidicapsa, Acidobacteriaceae, Lentzea, Staphylococcus, Plesiomonas, Dysgonomonas, Pseudonocardia, and Ellin6075. Conclusions: We found that the diversity of the gut microbiome declined after neoadjuvant PD- I antibody immunotherapy plus chemotherapy and surgery. Patients with pCR had different types and proportions of gut microbiota before treatment compared to those without pCR. We also observed the difference between patients with or without >= grade 3 AEs. The taxonomic features of the gut microbiome are potential biomarkers that could predict the pathological response and AEs.
WOS关键词PLUS CHEMOTHERAPY
资助项目Medical and Health Technology Plan of Zhejiang Province[2019KY330] ; Medical and Health Technology Plan of Zhejiang Province[2020KY057] ; Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province[2022E10021]
WOS研究方向Oncology ; Research & Experimental Medicine
语种英语
WOS记录号WOS:000777131800001
出版者AME PUBL CO
资助机构Medical and Health Technology Plan of Zhejiang Province ; Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/128241]  
专题中国科学院合肥物质科学研究院
通讯作者Chen, Qixun; Wang, Changchun
作者单位1.Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC,Canc Hosp,Dept Thorac, Hangzhou, Peoples R China
2.Chinese Acad Sci, Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp,Inst Basic Med & Canc IBMC,Dept Pharm, Hangzhou, Peoples R China
3.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Thorac Surg,Key Lab Prevent Diag & Therapy U, Hangzhou 310022, Peoples R China
推荐引用方式
GB/T 7714		 Xu, Liwei,Qi, Yajun,Jiang, Youhua,et al. Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy[J]. ANNALS OF TRANSLATIONAL MEDICINE,2022.
APA Xu, Liwei.,Qi, Yajun.,Jiang, Youhua.,Ji, Yongling.,Zhao, Qiang.,...&Wang, Changchun.(2022).Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy.ANNALS OF TRANSLATIONAL MEDICINE.
MLA Xu, Liwei,et al."Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy".ANNALS OF TRANSLATIONAL MEDICINE (2022).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。